Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.67 |
| ▸ | PGR | P06401 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | AR | P10275 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11877858 | 0.96 | NR3C1 (0.73) | NR3C1CYP3A4PGRMEN1KMT2A | |
| SCHEMBL11877864 | 0.96 | NR3C1 (0.73) | NR3C1CYP3A4PGRMEN1KMT2A | |
| SCHEMBL19726399 | 0.93 | CYP3A4 (0.64) | NR3C1CYP3A4PGRMEN1KMT2A | |
| SCHEMBL11811743 | 0.90 | CYP3A4 (0.58) | NR3C1CYP3A4PGRMEN1KMT2A | |
| SCHEMBL11811751 | 0.90 | CYP3A4 (0.58) | NR3C1CYP3A4PGRMEN1KMT2A | |
| SCHEMBL19715900 | 0.90 | HIF1A (0.68) | NR3C1CYP3A4PGRMEN1KMT2A | |
| SCHEMBL11328349 | 0.89 | HIF1A (0.61) | NR3C1CYP3A4PGRMEN1KMT2A | |
| SCHEMBL11328354 | 0.89 | HIF1A (0.61) | NR3C1CYP3A4PGRMEN1KMT2A | |
| SCHEMBL11122958 | 0.89 | NR3C1 (0.65) | NR3C1CYP3A4PGRMEN1KMT2A | |
| SCHEMBL12563067 | 0.87 | CYP3A4 (0.59) | NR3C1CYP3A4PGRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360805-A1 | MOTOR-ASSOCIATED NEURODEGENERATIVE DISEASE AND METHODS OF TREATMENT | Verge Analytics, Inc. | 2017-12-21 | — | — | US | disclosed |
| US-20170360805-A1 | MOTOR-ASSOCIATED NEURODEGENERATIVE DISEASE AND METHODS OF TREATMENT | Verge Analytics, Inc. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360805-A1 | MOTOR-ASSOCIATED NEURODEGENERATIVE DISEASE AND METHODS OF TREATMENT | TARDBP, SMN1; SMN2, GRN | NR3C1 3115/4885CYP3A4 4778/4885PGR 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.